Medications

US approves highly anticipated Eli Lilly weight loss drug

The US Food and Drug Administration (FDA) on Wednesday announced it had approved Eli Lilly's highly anticipated weight loss drug Zepbound, the latest entrant in a field of powerful—and lucrative—new obesity medicines.

Inflammatory disorders

A promising target to fight inflammatory bowel diseases

Inflammatory bowel diseases (IBDs), such as Crohn's disease or ulcerative colitis, arise when there is a dysregulation of the cell signaling pathways controlling the maintenance of homeostasis in the gut, leading to a chronic ...

Medical research

Clinical trials: Two arms are better than one

The German Institute for Quality and Efficiency in Health Care (IQWiG) has responded critically to a reflection paper by the European Medicines Agency (EMA) on the approval of new drugs based on single-arm studies.

Diseases, Conditions, Syndromes

Q&A: Vaccines, variants and COVID-19 trends

COVID-19 hospitalizations in the United States were on the rise for weeks heading into mid-September, right as updated COVID-19 vaccines from Pfizer and Moderna started to be distributed across the country.

page 8 from 40